Pharmafile Logo
Pharmafocus logo
Advanced Search

Valeant

Showing 15 posts of 90 posts found.

valeant

Former Valeant executive and Philidor CEO charged with fraud

November 18, 2016
Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud

Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …

News
valeant

Valeant’s tough year gets worse with Q3 loss of $1.22 billion

November 9, 2016
Research and Development Q3, Valeant, loss

It’s easy to say that Valeant hasn’t had a great year so far. Unfortunately for those concerned, the outlook for …

News
valeant

Hard times continue for Valeant as ex-CEO investigated for fraud

November 1, 2016
Manufacturing and Production CEO, Valeant, Valeant Pharmaceuticals, accounting, fraud

Valeant Pharmaceuticals continues to have a tough time after Bloomsberg broke the story of how former CEO J. Michael Pearson …

News
logo-int-corp2

Concordia founder resigns and will step down once replacement found

October 25, 2016
Manufacturing and Production CEO, Concordia, Mark Thompson, Valeant

Concordia International Corp., the Ontario-based company, has announced that its founder, Chairman and Chief Executive Officer, Mark Thompson, will leave …

News

Cipla receives FDA approval for generic version of Valeant antidepressant

August 30, 2016
Manufacturing and Production, Sales and Marketing Cipla, FDA, Valeant, Wellbutrin

Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the …

News
paul_herendeen

Valeant appoints new executive VP of finance and CFO

August 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Valeant, appointment

Valeant has announced the appointment of Paul S. Herendeen as executive vice president, who will also take over as chief …

Appointment
gavel

Former shareholders sue Valeant, alleging “vast fraud”

August 19, 2016
Medical Communications, Sales and Marketing Valeant, fraud, lawsuit, t rowe price

Valeant Pharmaceuticals has confirmed that it is being sued by one its former largest shareholders, T Rowe Price, who claim …

News
shutterstock_92671375

Valeant under criminal investigation

August 11, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, investigation

Valeant Pharmaceuticals International is currently under investigation by the US attorney’s office in Manhattan over suspicions that the firm intentionally …

News
shutterstock_138095450

Valeant stock rises despite weak Q2 results

August 10, 2016
Research and Development, Sales and Marketing Valeant, financial results

Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …

News
joseph_papa

Management shake-up at Valeant as Papa expands senior team

August 9, 2016
Manufacturing and Production, Sales and Marketing Valeant, joseph papa, management, shake up

Joseph Papa continues to remodel the plagued Valeant Pharmaceuticals, as a senior management shake-up has seen several new arrivals and …

News
needles

Valeant receives complete response letter from FDA on glaucoma drug

July 22, 2016
Medical Communications, Sales and Marketing FDA, Glaucoma, Valeant

Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA rejecting their new drug application …

News
doc_writing

FDA panel unanimously recommends approval of Valeant’s brodalumab with conditions

July 20, 2016
Research and Development, Sales and Marketing FDA, Valeant, brodalumab

Valeant has announced that the US Food and Drug Administration’s (FDA) dermatologic and ophthalmic drugs advisory committee has recommended brodalumab …

News
fda_sign_web

Valeant’s psoriasis drug “difficult to assess”, according to FDA staff

July 18, 2016
Research and Development, Sales and Marketing FDA, Valeant, psoriasis

Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …

News
astrazeneca_building_white

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …

News
pharma_pill_manufacturing

Valeant plots significant investment in Canadian operations

June 20, 2016
Manufacturing and Production, Sales and Marketing Canada, Valeant, manufacturing

Valeant Pharmaceuticals (NYSE: VRX) has announced that it plans to expand its Canadian operations with a $27.5 million expansion of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025